Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective,multicenter trial HIT 2000 confirming the prognostic impact of histology

摘要

This study was designed to confirm the previously observed favorable survival rates and prognostic factors in young children with nonmetastatic medulloblastoma (MB) treated with postoperative chemotherapy alone. Patients who received a diagnosis during the period January 2001 through December 2005 and who were aged <4 years received 3 cycles of postoperative systemic multiagent chemotherapy and intraventricular metho-trexate. In cases of complete remission, treatment was terminated after 2 additional cycles of chemotherapy. Otherwise, secondary surgery, radiotherapy, and consolidation chemotherapy were recommended. At a median follow-up of 4.5 years, the 5-year event-free survival (EFS) and overall survival (OS) rates ( + standard error) for 45 patients (median age, 2.5 years) were 57% + 8% and 80% ± 6%, respectively. Nineteen patients with desmoplasticodular MB variants had better 5-year EFS and OS rates (90% + 7% and 100% + 0%, respectively) than did 23 patients with classic MB (30% ± 11% and 68% + 10%, respectively; P < .001 for EFS; P = .008 for OS). Five-year EFS and OS rates for 3 children with anaplastic MB were 33% + 27%. Desmoplasticodular histology was an independent prognostic factor for EFS. Twenty-nine of 30 patients without postoperative residual tumor remained in continuous complete remission. Our results confirm that histology of MB variants is a strong prognostic factor in this age group. Sustained tumor control can be achieved by this chemotherapy regimen in young children with desmoplasticodular MB variants. For children with non-desmoplasticon-nodular MB variants, for which predominantly local relapses lead to less favorable survival rates, local radiotherapy has been introduced after chemotherapy since 2006.